You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ):“納米炭鐵混懸注射液”獲批藥物臨牀試驗
格隆匯 05-16 18:57

格隆匯5月16日丨萊美藥業(300006.SZ)公佈,近日,公司控股子公司四川瀛瑞醫藥科技有限公司(“瀛瑞醫藥”)向國家藥品監督管理局提交的“納米炭鐵混懸注射液”獲得藥物臨牀試驗默示許可並取得由國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》。

納米炭鐵混懸注射液(納米炭鐵)是在公司產品納米炭混懸注射液基礎上研究開發的新一代納米藥物,以 Fe2+作為抗癌有效成分,納米炭作為Fe2+的載體,通過調控鐵死亡通路發揮抗癌作用。納米炭鐵通過瘤內注射,具有抑制腫瘤生長的功能。納米炭鐵是一種新機理抗癌藥物,與相關化療藥物聯合應用,預期在充分發揮各自抗癌優勢的情況下使毒副作用保持在可以控制的範圍內,進一步提高聯合治療癌症的療效。

目前,納米炭鐵已經啟動臨牀研究,擬開發適應症為多種實體癌症,例如胰腺癌、結直腸癌等。根據國家藥品審評中心的政策法規,I 期臨牀試驗的對象為經過標準治療無效或者無標準治療的晚期實體癌症患者。

目前,尚無納米炭鐵同類產品上市或處於在研末期,也未有涉及外源性直接給予Fe2+靶向鐵死亡通路的藥物上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account